HK1064304A1 - Hdl for the treatment of stroke and other ischemicconditions - Google Patents

Hdl for the treatment of stroke and other ischemicconditions

Info

Publication number
HK1064304A1
HK1064304A1 HK04107205A HK04107205A HK1064304A1 HK 1064304 A1 HK1064304 A1 HK 1064304A1 HK 04107205 A HK04107205 A HK 04107205A HK 04107205 A HK04107205 A HK 04107205A HK 1064304 A1 HK1064304 A1 HK 1064304A1
Authority
HK
Hong Kong
Prior art keywords
hdl
stroke
treatment
ischemicconditions
prophylaxis
Prior art date
Application number
HK04107205A
Other languages
English (en)
Inventor
Hubsch Alphonse
Lang Markus
Lerch Peter
Paterno Roberto
Original Assignee
Csl Behring Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01120026A external-priority patent/EP1285662A1/en
Application filed by Csl Behring Ag filed Critical Csl Behring Ag
Publication of HK1064304A1 publication Critical patent/HK1064304A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
HK04107205A 2001-08-20 2004-09-17 Hdl for the treatment of stroke and other ischemicconditions HK1064304A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31360501P 2001-08-20 2001-08-20
EP01120026A EP1285662A1 (en) 2001-08-20 2001-08-20 Reconstituted HDL for the treatment of stroke and ischemic conditions
PCT/EP2002/009294 WO2003018047A2 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions

Publications (1)

Publication Number Publication Date
HK1064304A1 true HK1064304A1 (en) 2005-01-28

Family

ID=26076691

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04107205A HK1064304A1 (en) 2001-08-20 2004-09-17 Hdl for the treatment of stroke and other ischemicconditions

Country Status (11)

Country Link
US (2) US20040266660A1 (ru)
EP (1) EP1425031B8 (ru)
JP (1) JP4284177B2 (ru)
AT (1) ATE396736T1 (ru)
AU (1) AU2002340825B2 (ru)
CA (1) CA2457840C (ru)
DE (1) DE60226881D1 (ru)
ES (1) ES2304452T3 (ru)
HK (1) HK1064304A1 (ru)
WO (1) WO2003018047A2 (ru)
ZA (1) ZA200401360B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668645A (zh) * 2002-05-17 2005-09-14 埃斯佩里安医疗公司 治疗缺血再灌注的方法和组合物
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
JP5601750B2 (ja) * 2007-03-01 2014-10-08 シーエスエル、リミテッド 糖尿病患者の内皮機能異常の治療
AU2007200908B2 (en) * 2007-03-01 2012-08-16 Csl Limited Treatment of endothelial dysfunction in diabetic patients
EA021344B1 (ru) 2009-06-25 2015-05-29 Тетра Сиа Терапевтические комбинации никотиновой кислоты и мелдония
WO2011006994A1 (en) 2009-07-16 2011-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Hdl comprising a therapeutic agent and use in therapy
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
WO2012103163A2 (en) * 2011-01-25 2012-08-02 The Cleveland Clinic Foundation Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
CN103443123B (zh) 2011-02-07 2020-05-29 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
EP2688584A4 (en) * 2011-03-25 2015-05-20 Univ Columbia PEGYLATED HUMAN HDL PARTICLES AND METHOD OF PREPARING THEM
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
RU2016144908A (ru) 2014-05-02 2018-06-05 Серени Терапеутикс Холдинг Са Маркеры hdl-терапии
EP3668549B1 (en) 2017-08-10 2024-05-15 Abionyx Pharma SA Apomers
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding CARGOMÈRES
WO2021191266A1 (en) 2020-03-25 2021-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hdl for the treatment of lung infections
CN115427064A (zh) 2020-04-16 2022-12-02 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗急性病况的方法
US20240000948A1 (en) 2020-10-01 2024-01-04 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
US20230372532A1 (en) * 2020-10-05 2023-11-23 Northwestern University Targeted ph sensitive liposomes
EP4322746A1 (en) 2021-04-15 2024-02-21 Abionyx Pharma SA Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
CA2377999A1 (en) * 1999-07-08 2001-01-18 Tularik Inc Compositions and methods for raising hdl cholesterol levels
GB9919713D0 (en) * 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
AUPQ429399A0 (en) 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use

Also Published As

Publication number Publication date
ATE396736T1 (de) 2008-06-15
WO2003018047A2 (en) 2003-03-06
US7491693B2 (en) 2009-02-17
EP1425031A2 (en) 2004-06-09
JP4284177B2 (ja) 2009-06-24
ZA200401360B (en) 2005-08-31
DE60226881D1 (de) 2008-07-10
EP1425031B8 (en) 2008-09-03
AU2002340825B2 (en) 2007-07-05
US20080108550A1 (en) 2008-05-08
JP2005501110A (ja) 2005-01-13
CA2457840C (en) 2011-10-11
EP1425031B1 (en) 2008-05-28
ES2304452T3 (es) 2008-10-16
CA2457840A1 (en) 2003-03-06
US20040266660A1 (en) 2004-12-30
WO2003018047A3 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
HK1064304A1 (en) Hdl for the treatment of stroke and other ischemicconditions
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
CY1110407T1 (el) Συνθεση για χορηγηση σιδηρου για την θεραπεια του συνδρομου σπασμωδικου σκελους
DK0665749T3 (da) Sammensætning til behandling af Parkinsons sygdom
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
AU8699101A (en) Methods for treating muscle injuries
WO2002003911A3 (en) Prevention and treatment of alzheimer's disease
BR0110573A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
BRPI0409865A (pt) injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia
WO2002007678A3 (en) Mu-conopeptides
SE0004101D0 (sv) New use
HK1092045A1 (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
MY142646A (en) Chemokine receptor antagonists and methods of use therefor
WO2003029221A8 (de) Tetrahydroisochinoline, ihre herstellung und verwendung als schmerzmittel
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
UA29106A (ru) Способ лечения вибрационной болезни
RU2001104567A (ru) Способ лечения эректильной дисфункции
RU2004105675A (ru) Способ комплексного лечения язв роговицы
UA41200A (ru) Способ консервативного лечения остеоартроза
UA36766A (ru) Способ лечения больных хроническим алкогольным гепатитом
UA33498A (ru) Способ лечения терапевтически разистентных форм шизофрении
UA38006A (uk) Хондропротективний препарат
RU2003135700A (ru) Способ лечения хирургической инфекции

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: DELETION OF INVENTORS: PETER G. LERCH - ROBERTO PATERNO

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180820